Document Detail


Hematologic response in patients with aplastic anemia after long-term administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
MedLine Citation:
PMID:  9444448     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty patients with aplastic anemia underwent long-term administration (10 weeks) of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in doses from 50 to 800 micrograms/m2 per day by intravenous infusion or 50 to 100 micrograms/m2 per day by subcutaneous injection and re-combinant human erythropoietin (rhEPO) in doses ranging from 2000 to 8000 IU/m2 per day by intravenous injection three times a week for at least 4 weeks. The goal was to evaluate whether therapy ameliorated pancytopenia in these patients as well as to determine its safety. All assessable patients showed a substantial increase in absolute neutrophil count, with a recovery of myeloid components (granulocyte series) in the bone marrow, after 2 to 10 weeks of treatment. An increase > 1.5 g/dL in hemoglobin (Hb) concentration was observed in 2 patients (10%). A decrease > 50% in red cell transfusion requirement was observed in 2 patients (10%). Seven patients showed recovery of neutropenia, anemia, and platelet count. In addition, there was no serious infection before or during therapy, and side effects were mild. Of the 20 patients, 3 showed a dramatic improvement in severe anemia after 10 weeks of treatment accompanying a recovery of erythroid components in the bone marrow. They no longer require red cell transfusions and have had normal Hb concentrations and normal ferrokinetics. These results indicate that long-term administration of rhG-CSF and rhEPO may benefit some patients with aplastic anemia. Further studies will be necessary to elucidate the mechanism by which rhGCSF and rhEPO stimulate hematopoiesis and improve hematologic abnormalities in these patients.
Authors:
S Yonekura; H Kawada; S Watanabe; A Masumoto; Y Ogawa; R Fukuda; H Nishihira; S Matsuyama; S Katoh; H Mouri; S Motomura; S Shionoya; T Hotta
Related Documents :
12380888 - Haematological alterations in leprosy patients treated with dapsone.
16163188 - Anemia in multiple myeloma.
16048488 - Management of acute painful crises in sickle cell disease.
9155308 - Religious restrictions and the trauma patient.
792628 - Candida meningitis. report of seven cases and review of the english literature.
3996938 - Gastrin sensitivity in duodenal ulcer.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  19     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:    1997 Nov-Dec
Date Detail:
Created Date:  1998-03-05     Completed Date:  1998-03-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1394-407     Citation Subset:  IM    
Affiliation:
Fourth Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Anemia, Aplastic / blood*,  therapy*
Blood Cell Count
Child
Child, Preschool
Erythropoietin, Recombinant / adverse effects,  therapeutic use*
Female
Granulocyte Colony Stimulating Factor, Recombinant / adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Pancytopenia / blood,  drug therapy
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Granulocyte Colony Stimulating Factor, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimization of antihypertensive therapy with a novel, extended-release formulation of diltiazem: re...
Next Document:  Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insu...